Closed transaction

Sale of Mabtech, a Swedish life science products company

Advised by
Client
Counterparty
Deal stage
Closed transaction
Service
Sell
Sector
Healthcare
Sub-sector
Biotech/Pharma Services
Market
EMEA
Contact
hew@evli.com

Deal details

We have been mandated by the owners of a Swedish biotech company in connection with the evaluation of a potential sale of the Company. The company is focused on developing and manufacturing high-quality monoclonal antibodies, kits, and instruments for analyses of immune responses and the immune system in e.g. infectious diseases, cancer, allergy, transplantations, vaccines. The products are mainly sold for research, but are also sold to diagnostic companies. The company is experiencing rapid growth and strong profitability. During the 12 months to June 2019 the company recorded sales of ca €12m (36% growth) and EBITDA margin in excess of 45%.

We ran a focused but highly competitive process focusing on potential PE buyers with experience / knowledge in the Life Science sector and select industrial buyers. Interest from PE buyers was clearly stronger. We focused on early pre-marketing meetings with potential buyers to describe the company and opportunity. We got 5 potential buyers to complete their commmercial due diligence even before indicative offers, which made us comfortable about the level of commitment to the deal. We ran the key negotiation about valuation around the time of indicative offers and got most of the serious bidders to increase their offers. We decided to move forward with only two potential buyers in a DD phase in order to be able to run a focused on quick process. We managed to sign the deal with a local Swedish PE house in less than 3 weeks after indicative offers. No conditions to closing - closing will take place on Dec 12.

Henrik Westling Evli Corporate Finance AB Henrik joined Evli in May 2002 following Evli’s acquisition of Arthur Andersen’s Nordic Corporate Finance operations. View profile

More by Evli Corporate Finance AB

More deals in Healthcare

Sell-side advisory

Allied Group has acquired majority stake in Tzamal Medical.

Where
Israel
Year
2026
Sell-side advisory

PharmaX Solutions was sold to BioPhorum.

Where
Germany
Year
2026
Sell-side advisory

Nostos Genomics was sold to Limbus Medical Technologies (varvis®).

Where
Germany
Year
2025

More Healthcare

More deals in Europe

Sell-side advisory

Ocean Property Services Group sold to Lomond.

Where
United Kingdom
Year
2026
Advisory

John Henry Group.

Where
United Kingdom
Year
2026
Advisory

houzy and myky join forces under Swiss Digital Home AG.

Where
Switzerland
Year
2026
Sell-side advisory

Fibreactive sold to discoverIE Group plc.

Where
United Kingdom
Year
2026

More Europe

Membership

Gain worldwide reach with CapFive M&A professionals

The professionals of CapFive have been carefully selected on the basis of reputation, relationships, proven track record and knowledge of local markets.

Become a member

Get in touch

Find an adviser.

From a first valuation to signed completion, CapFive member firms advise on sell-side, buy-side, corporate finance and debt.

Share what you are planning and we will connect you with an adviser who has done it before, and who can bring in colleagues across borders when the deal needs them.

Contact us